Reactive Oxygen Species and Hypoxia Inducible Factor-1Α Serve As Important Vascular Stabilizing Elements in Tumors Following Radiotherapy
B.J Moeller,Y Cao,Z Vujaskovic,M.W Dewhirst
DOI: https://doi.org/10.1016/s0360-3016(03)01198-2
2003-01-01
Abstract:Purpose/Objective: Recent studies have shown that combining radiotherapy (RT) and anti-angiogenic agents can result in supra-additive tumor control ( 1Camphausen K, Menard C. Angiogenesis inhibitors and radiotherapy of primary tumors. Expert Opin Biol Ther 2002;2:477–481.) suggesting that RT may stimulate a pro-angiogenic tumor environment. Little is known, though, about the mechanisms linking RT to angiogenesis. We have previously found that RT upregulates tumor hypoxia inducible factor-1a (HIF-1α) activity ( 2In press.). As HIF-1α is an important regulator of tumor angiogenesis ( 3Semenza, GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in Mol Med 2002;8:S62–S67.), its activation may be necessary for the survival of tumor vasculature following RT. Thus, understanding the mechanism whereby RT leads to HIF-1α activation may uncover important therapeutic opportunities. Our previous data implicate tumor reoxygenation and free radical species in RT-induced HIF-1α activation. Therefore, we investigate here whether reactive oxygen species (ROS) are involved in stabilizing HIF-1α and, thereby, tumor vasculature following RT. We utilize a novel mimetic of Superoxide Dismutase (SOD), a potent scavenger of diverse ROS ( 4Vujaskovic Z, Batinic-Haberle I, Rabbani ZN, Feng QF, Kang SK, Spasojevic I, et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 2002;15:857–863.), to establish a causative link between ROS, HIF-1α, and post-RT angiogenesis. Materials/Methods: A HIF-1α reporter construct was stably transfected into a murine mammary carcinoma line (4T1). 5×103 4T1 transfectants were transplanted beneath the fascia under a dorsal skinfold window chamber in each BALB/C mouse used in these experiments. Once tumors reached an appropriate size, the mice were restrained, and the skinfold was exposed to a total of 1500cGy of radiation in 3 fractions (500cGy each). Following RT, animals were randomized to treatment with a SOD mimetic (AEOL-10113, 6mg/kg), or PBS. Intravital fluorescence microscopy observations were performed daily thereafter to quantify HIF-1α activity, as judged by reporter signal fluorescence intensity. To monitor ROS in vivo, wild-type 4T1 tumors were grown in window chambers and treated as described above. Then, mice were anesthetized, and the tumor tissue was suffused with a fluorescent ROS-sensitive dye, carboxy-2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA). Global tumor ROS levels were then monitored using fluorescence intravital microscopy. Results: Consistent with previous findings, irradiated tumors increased overall HIF-1α expression following RT by approximately 2-fold (n=10, p<0.001), peaking at 48 hours after RT. ROS within the tumor also increased significantly following RT (n=5, p<0.001), preceding the peak in HIF-1α activity, with maximal signal at 24 hours post-RT. When an ROS scavenger was administered immediately following RT, tumor ROS (n=5, p<0.001) and HIF-1α upregulation (n=5, p<0.001) were both suppressed. When the SOD mimetic was given 24 hours after radiation, however, HIF-1α upregulation was not blocked. Importantly, when HIF-1α activation was inhibited with the ROS scavenger, a striking vascular destabilization resulted, followed by a reduction in tumor volume. Conclusions: To our knowledge, this is the first direct, in vivo, evidence that ROS play a role in tumor angiogenesis. Moreover, it is the first demonstration that ROS are generated after radiation by mechanisms distinct from the immediate effects of ionizing radiation. Following from these findings, it was demonstrated that free radical scavenging — achievable with small-molecule pharmaceuticals — is sufficient to block HIF-1α activation and decrease endothelial cell survival following RT. Further studies are warranted to investigate the feasibility of using this exciting approach in more clinically-relevant tumor models and radiation treatment doses/schedules.